IL288655A - Preparations and methods for the treatment of central nervous system disorders - Google Patents

Preparations and methods for the treatment of central nervous system disorders

Info

Publication number
IL288655A
IL288655A IL288655A IL28865521A IL288655A IL 288655 A IL288655 A IL 288655A IL 288655 A IL288655 A IL 288655A IL 28865521 A IL28865521 A IL 28865521A IL 288655 A IL288655 A IL 288655A
Authority
IL
Israel
Prior art keywords
compositions
methods
nervous system
central nervous
system disorders
Prior art date
Application number
IL288655A
Other languages
English (en)
Hebrew (he)
Original Assignee
Paxmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paxmedica Inc filed Critical Paxmedica Inc
Publication of IL288655A publication Critical patent/IL288655A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL288655A 2019-06-07 2021-12-02 Preparations and methods for the treatment of central nervous system disorders IL288655A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858621P 2019-06-07 2019-06-07
PCT/US2020/031217 WO2020247127A1 (en) 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
IL288655A true IL288655A (en) 2022-02-01

Family

ID=73652889

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288655A IL288655A (en) 2019-06-07 2021-12-02 Preparations and methods for the treatment of central nervous system disorders

Country Status (8)

Country Link
US (1) US20220226268A1 (enExample)
EP (1) EP3979985A4 (enExample)
JP (1) JP7749169B2 (enExample)
CN (1) CN114340597B (enExample)
AU (1) AU2020288999A1 (enExample)
CA (1) CA3142842A1 (enExample)
IL (1) IL288655A (enExample)
WO (1) WO2020247127A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867487A (zh) * 2020-07-29 2023-10-10 完美日光有限公司 苏拉明的制造方法
US20230390226A1 (en) * 2020-10-22 2023-12-07 Paxmedica, Inc. Intranasal administration of suramin for treating nervous system disorders
IL302224A (en) * 2020-10-22 2023-06-01 Paxmedica Inc Administration of anti-purinergic preparations for the treatment of disorders of the nervous system
WO2023027994A1 (en) * 2021-08-23 2023-03-02 Paxmedica, Inc. Methods for treating nervous system disorders with antipurinergic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002266A1 (en) * 1984-10-12 1986-04-24 United States Of America, Represented By The Unite Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
AU6527300A (en) * 1999-08-11 2001-03-05 Josef Pitha Potentiation of inclusion complex formation of cyclodextrin derivatives
US20050063940A1 (en) * 2002-02-25 2005-03-24 Sveinbjorn Gizurarson Bioadhesive agent
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
EP1802287A2 (en) * 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
FR2912591B1 (fr) * 2007-02-12 2009-05-01 Oberthur Card Syst Sa Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile.
AR062239A1 (es) * 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
US20120070487A1 (en) * 2010-03-24 2012-03-22 Aegis Therapeutics Llc Alkylsaccharide compositions with nutraceuticals
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
FR3025110B1 (fr) 2014-09-02 2016-12-23 Univ Francois-Rabelais De Tours Dispositif de pulverisation nasale de produit fluide
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
JP7093559B2 (ja) * 2016-04-12 2022-06-30 トライジェミナ, インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
WO2018148262A1 (en) * 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
CN118697876A (zh) * 2017-02-09 2024-09-27 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Also Published As

Publication number Publication date
CA3142842A1 (en) 2020-12-10
AU2020288999A1 (en) 2022-02-03
JP7749169B2 (ja) 2025-10-06
JP2022535920A (ja) 2022-08-10
US20220226268A1 (en) 2022-07-21
CN114340597A (zh) 2022-04-12
WO2020247127A1 (en) 2020-12-10
EP3979985A1 (en) 2022-04-13
CN114340597B (zh) 2025-01-28
EP3979985A4 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
IL285649A (en) Azepino-indoles and other heterocyclics for the treatment of brain disorders
IL290575A (en) Preparations and methods for the treatment of disorders related to repetitive DNA
IL275506A (en) Preparations and methods for the treatment of central nervous system disorders
IL289173A (en) Preparations and methods for the treatment of central nervous system disorders
EP4010072A4 (en) TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
IL275562A (en) Preparations and methods for the treatment of central nervous system disorders
EP3746135A4 (en) METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
IL286868A (en) Compounds and methods that monitor the expression of genes in the central nervous system
EP3999110A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES
EP3917620A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS
IL288655A (en) Preparations and methods for the treatment of central nervous system disorders
SG11202011151VA (en) Compositions and methods for reducing spliceopathy and treating rna dominance disorders
IL289172A (en) Preparations and methods for the treatment of central nervous system disorders
SG11202102349PA (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
IL270114B1 (en) Methods and compounds for the treatment of neurological diseases
IL275985A (en) Preparations and methods for the treatment of retinal disorders
IL279634A (en) Preparations and methods for the treatment and prevention of neurological disorders
IL287831A (en) Oxymetazoline compounds and methods for treating eye diseases
EP3917622A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO ANXIETY
IL274067A (en) Kinase inhibitors for the treatment of central and peripheral nervous system disorders
IL286571A (en) Compounds and methods for the treatment of neurodegenerative disorders
ES3063390T3 (en) Compositions and methods for treating inflammatory neurological disorders
EP3256151A4 (en) Methods and compositions for treating muscle disease and disorders
IL311852A (en) Preparations and methods for the treatment of neurological disorders
IL291639A (en) A method for treating mood disorders